Jeffrey L. Cleland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeffrey L. Cleland has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Ann Daugherty
3 shared publicationsChung Hsu
Pharmaceutical R & D, Genentech, Inc., 1 DNA Way, South San Francisco, California 94070
2 shared publicationsDennis Brooks
Pharmaceutical R & D, Genentech, Inc., 1 DNA Way, South San Francisco, California 94070
2 shared publicationsEileen T. Duenas
Departments of Pharmaceutical Research and Development, Genentech, Inc., South San Francisco, California 94080
2 shared publicationsJanet Yang
Quality Control, Genentech, Inc., South San Francisco, California
2 shared publicationsA Lim
1 shared publication
Latest Publications
- 1 April 2001
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 12 (2) , 212-219
Emerging protein delivery methods
- 1 April 2001
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 12 (2) , 212-219
Emerging protein delivery methods
- 1 March 2001
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 90 (3) , 310-321
A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody
- 1 March 2001
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 90 (3) , 310-321
A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody
- 1 December 1998
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 87 (12) , 1489-1495
Development of a single‐shot subunit vaccine for HIV‐1. 5. Programmable in vivo autoboost and long lasting neutralizing response
The subunit vaccine for HIV-1, recombinant glycoprotein 120 (rgp120), was used as a model antigen to evaluate the potential for a pulsatile single immunization vaccine formulation consisting of poly(lactic-co-glycolic) acid (PLGA) microspheres. We designed rgp120 PLGA microsphere formulations that provide a pulse of rgp120 at 1 to 6 months (depending on the polymer) after administration, mimicking another immunization. In these studies, the in vitro pulse of rgp120 correlated well with the observed in vivo autoboost as measured by an increase in anti-gp120 antibodies in guinea pigs. The immune response to the rgp120 PLGA microsphere formulations was increased by adding the soluble form of the saponin-derived adjuvant, QS-21. The use of small microspheres, however, did not increase the humoral response to rgp120. A single immunization with rgp120 PLGA microspheres resuspended in soluble rgp120 and QS-21 elicited neutralizing antibody titers that were comparable to titers obtained from two immunizations of rgp120 and QS-21 at the same total dose. Administration of rgp120 PLGA microspheres in baboons resulted in high, long-lasting neutralizing antibody titers that were greater than repeated immunizations with soluble rgp120 and QS-21. These studies also indicated that a continuous release of QS-21 at the injection site may provide a greater immune response than a bolus injection. Overall, this work demonstrated that PLGA microsphere formulations may be designed to provide in vivo pulses of an antigen eliminating the need for repeated immunizations.
- 1 December 1998
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 87 (12) , 1489-1495
Development of a single‐shot subunit vaccine for HIV‐1. 5. Programmable in vivo autoboost and long lasting neutralizing response
The subunit vaccine for HIV-1, recombinant glycoprotein 120 (rgp120), was used as a model antigen to evaluate the potential for a pulsatile single immunization vaccine formulation consisting of poly(lactic-co-glycolic) acid (PLGA) microspheres. We designed rgp120 PLGA microsphere formulations that provide a pulse of rgp120 at 1 to 6 months (depending on the polymer) after administration, mimicking another immunization. In these studies, the in vitro pulse of rgp120 correlated well with the observed in vivo autoboost as measured by an increase in anti-gp120 antibodies in guinea pigs. The immune response to the rgp120 PLGA microsphere formulations was increased by adding the soluble form of the saponin-derived adjuvant, QS-21. The use of small microspheres, however, did not increase the humoral response to rgp120. A single immunization with rgp120 PLGA microspheres resuspended in soluble rgp120 and QS-21 elicited neutralizing antibody titers that were comparable to titers obtained from two immunizations of rgp120 and QS-21 at the same total dose. Administration of rgp120 PLGA microspheres in baboons resulted in high, long-lasting neutralizing antibody titers that were greater than repeated immunizations with soluble rgp120 and QS-21. These studies also indicated that a continuous release of QS-21 at the injection site may provide a greater immune response than a bolus injection. Overall, this work demonstrated that PLGA microsphere formulations may be designed to provide in vivo pulses of an antigen eliminating the need for repeated immunizations.
- 6 February 1998
- Published by Wiley in Biotechnology Progress
- Vol. 14 (1) , 102-107
Solvent Evaporation Processes for the Production of Controlled Release Biodegradable Microsphere Formulations for Therapeutics and Vaccines
Novel drug delivery technologies have now evolved to allow the clinical production of new dosage forms. One new form, biodegradable microspheres, may have utility as a second‐generation formulation for parenterally administered proteins and peptides or may be required for the success of some new chemical entities. Here, we have focused on the use of poly(lactic‐co‐glycolic acid) (PLGA) microspheres to provide a continuous delivery of therapeutic proteins or a pulsatile delivery of protein‐based vaccines. To date, our success with solvent evaporation processes has been primarily in the production of microspheres with a triphasic protein release pattern instead of a continuous release. However, with continued development efforts, this method may be used to produce continuous release protein formulations. While this review draws from our own work, there is a great deal of excellent research in this area at both universities and industrial laboratories. This work combined with our studies indicates that this technology holds much promise for new protein formulations that will provide improvements in patient care and, perhaps, increased efficacy.
- 6 February 1998
- Published by Wiley in Biotechnology Progress
- Vol. 14 (1) , 102-107
Solvent Evaporation Processes for the Production of Controlled Release Biodegradable Microsphere Formulations for Therapeutics and Vaccines
Novel drug delivery technologies have now evolved to allow the clinical production of new dosage forms. One new form, biodegradable microspheres, may have utility as a second‐generation formulation for parenterally administered proteins and peptides or may be required for the success of some new chemical entities. Here, we have focused on the use of poly(lactic‐co‐glycolic acid) (PLGA) microspheres to provide a continuous delivery of therapeutic proteins or a pulsatile delivery of protein‐based vaccines. To date, our success with solvent evaporation processes has been primarily in the production of microspheres with a triphasic protein release pattern instead of a continuous release. However, with continued development efforts, this method may be used to produce continuous release protein formulations. While this review draws from our own work, there is a great deal of excellent research in this area at both universities and industrial laboratories. This work combined with our studies indicates that this technology holds much promise for new protein formulations that will provide improvements in patient care and, perhaps, increased efficacy.
- 1 April 1997
- Published by Springer Nature in Pharmaceutical Research
- Vol. 14 (4) , 420-425
The Stability of Recombinant Human Growth Hormone in Poly(lactic-co-glycolic acid) (PLGA) Microspheres
Purpose. The development of a sustained release formulation for recombinant human growth hormone (rhGH) as well as other proteins requires that the protein be stable at physiological conditions...
- 1 April 1997
- Published by Springer Nature in Pharmaceutical Research
- Vol. 14 (4) , 420-425
The Stability of Recombinant Human Growth Hormone in Poly(lactic-co-glycolic acid) (PLGA) Microspheres
Purpose. The development of a sustained release formulation for recombinant human growth hormone (rhGH) as well as other proteins requires that the protein be stable at physiological conditions...
- 1 January 1994
- p. S21-6
Development of a single-shot subunit vaccine for HIV-1.
The successful development of an AIDS vaccine will require formulations that not only invoke the desired immunological response, but also are stable and easy to administer. A single shot MN rgp120 vaccine formulation comprised of MN rgp120 encapsulated in poly (lactic-coglycolic) acid (PLGA) microspheres was developed to provide an in vivo autoboost of antigen. These formulations were designed to yield an in vivo autoboost at 1, 2, 3 or 4-6 months. In addition, PLGA microspheres containing the adjuvant, QS21, were also prepared to provide an in vivo autoboost concomitant with antigen. In guinea pigs, these formulations yielded higher anti-MN rgp120 and anti-V3 loop antibody titers than alum formulations that were administered at higher antigen doses. Different doses of encapsulated MN rgp120 provided a clear and well-defined dose response curve for both anti-MN rgp120 and anti-V3 loop antibody titers. When soluble QS21 was mixed with the encapsulated MN rgp120, the antibody titers were increased by a factor of 5 over the titers with encapsulated MN rgp120 alone. An additional fivefold increase in antibody titers was observed for guinea pigs immunized with encapsulated MN rgp120 and QS21 on the same microspheres. These results suggest that the adjuvant properties of QS21 can be increased by microencapsulation in PLGA. Furthermore, antibodies induced by these preparations neutralized the MN strain of HIV-1. The neutralization titers for sera from animals immunized with MN rgp120-PLGA and soluble QS21 were greater than the titers obtained from guinea pigs that were treated with MN rgp120 and soluble QS21 at the same dose. Overall, these studies validate the in vivo autoboost concept, reveal a method for improving the adjuvant properties of QS21, and indicate the potential of future single shot vaccine formulations.
- 1 January 1994
- p. S21-6
Development of a single-shot subunit vaccine for HIV-1.
The successful development of an AIDS vaccine will require formulations that not only invoke the desired immunological response, but also are stable and easy to administer. A single shot MN rgp120 vaccine formulation comprised of MN rgp120 encapsulated in poly (lactic-coglycolic) acid (PLGA) microspheres was developed to provide an in vivo autoboost of antigen. These formulations were designed to yield an in vivo autoboost at 1, 2, 3 or 4-6 months. In addition, PLGA microspheres containing the adjuvant, QS21, were also prepared to provide an in vivo autoboost concomitant with antigen. In guinea pigs, these formulations yielded higher anti-MN rgp120 and anti-V3 loop antibody titers than alum formulations that were administered at higher antigen doses. Different doses of encapsulated MN rgp120 provided a clear and well-defined dose response curve for both anti-MN rgp120 and anti-V3 loop antibody titers. When soluble QS21 was mixed with the encapsulated MN rgp120, the antibody titers were increased by a factor of 5 over the titers with encapsulated MN rgp120 alone. An additional fivefold increase in antibody titers was observed for guinea pigs immunized with encapsulated MN rgp120 and QS21 on the same microspheres. These results suggest that the adjuvant properties of QS21 can be increased by microencapsulation in PLGA. Furthermore, antibodies induced by these preparations neutralized the MN strain of HIV-1. The neutralization titers for sera from animals immunized with MN rgp120-PLGA and soluble QS21 were greater than the titers obtained from guinea pigs that were treated with MN rgp120 and soluble QS21 at the same dose. Overall, these studies validate the in vivo autoboost concept, reveal a method for improving the adjuvant properties of QS21, and indicate the potential of future single shot vaccine formulations.